Neuroprotective effect of dexmedetomidine in brain tumor surgery

Evaluation of neuroprotective effect of dexmedetomidine in patients undergoing brain tumor resection?

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202008567047887

Enrollment

Registered

2020-08-25

Start date

2020-08-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Nervous System Diseases Anaesthesia

Interventions

total intravenous anesthesia

dexmedetomidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients aged 20-60 years, both sex, ASA class I and II, who undergo elective supratentorial tumor resection surgery

Exclusion criteria

Exclusion criteria: patient's refusal, pre-existing psychiatric disorders or cognitive dysfunction, cerebral infarction, frontal lesions A-V heart block, patients who need intraoperative blood transfusion or those who need postoperative mechanical ventilation surgery in prone position.

Design outcomes

Primary

Measure	Time frame
cerebral oxygen extraction ratio	—

Secondary

Measure	Time frame
cognitive function;hemodynamic changes heart rate and mean arterial pressure;complications e.g. PONV, hypotension , bradycardia	—

Countries

Egypt

Contacts

Public ContactMona Elghamry

lecturer

drmonagh19802000@gmail.com+201060101867

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026